Grants - Viral Hepatitis

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

Grant Source: 

The purpose of this FOA is to provide investigators working on the development of novel therapeutic products for HIV and HIV-associated co-infections (hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis) with a mechanism to request NIAID DAIDS preclinical services to fill gaps in their product development efforts and facilitate the advancement of promising therapeutics from bench to clinics.

Health Topics: